Cargando…

Myofiber HLA-DR expression is a distinctive biomarker for antisynthetase-associated myopathy

OBJECTIVES: To assess the value of major histocompatibility complex (MHC) class II antigen (HLA-DR) expression to distinguish anti-synthetase myopathy (ASM) from dermatomyositis (DM). METHODS: Muscle biopsies from patients with ASM (n = 33), DM without anti-synthetase antibodies (ASAb) (n = 17), and...

Descripción completa

Detalles Bibliográficos
Autores principales: Aouizerate, Jessie, De Antonio, Marie, Bassez, Guillaume, Gherardi, Romain K, Berenbaum, Francis, Guillevin, Loïc, Berezne, Alice, Valeyre, Dominique, Maisonobe, Thierry, Dubourg, Odile, Cosnes, Anne, Benveniste, Olivier, Authier, François Jérôme
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4210467/
https://www.ncbi.nlm.nih.gov/pubmed/25339355
http://dx.doi.org/10.1186/s40478-014-0154-2
_version_ 1782341375860146176
author Aouizerate, Jessie
De Antonio, Marie
Bassez, Guillaume
Gherardi, Romain K
Berenbaum, Francis
Guillevin, Loïc
Berezne, Alice
Valeyre, Dominique
Maisonobe, Thierry
Dubourg, Odile
Cosnes, Anne
Benveniste, Olivier
Authier, François Jérôme
author_facet Aouizerate, Jessie
De Antonio, Marie
Bassez, Guillaume
Gherardi, Romain K
Berenbaum, Francis
Guillevin, Loïc
Berezne, Alice
Valeyre, Dominique
Maisonobe, Thierry
Dubourg, Odile
Cosnes, Anne
Benveniste, Olivier
Authier, François Jérôme
author_sort Aouizerate, Jessie
collection PubMed
description OBJECTIVES: To assess the value of major histocompatibility complex (MHC) class II antigen (HLA-DR) expression to distinguish anti-synthetase myopathy (ASM) from dermatomyositis (DM). METHODS: Muscle biopsies from patients with ASM (n = 33), DM without anti-synthetase antibodies (ASAb) (n = 17), and normal muscle biopsy (n = 10) were first reviewed. ASAb included anti-Jo1 (26/33), anti-PL12 (4/33), anti-PL7 (2/33), and anti-EJ (1/33). Immunohistochemistry was performed for MHC-I/HLA-ABC, MHC-II/HLA-DR, membrane attack complex (C5b-9), neural cell adhesion molecule (NCAM)/CD56 expression, and inflammatory cell subsets. Twenty-four ASM and 12 DM patients from another center were added for HLA-DR evaluation. RESULTS: Ubiquitous myofiber HLA-ABC expression was equally observed in ASM and DM (93.9% vs 100%, NS). In contrast, myofiber HLA-DR expression was found in 27/33 (81.8%) ASM (anti-Jo1: 23/26, 88.5%; others: 5/7, 71.4%) vs 4/17 (23.5%) DM patients (p < 0.001). HLA-DR was perifascicular in ASM, a pattern not observed in DM. In addition, C5b-9 deposition was observed on sarcolemma of non-necrotic perifascicular fibers in ASM, while, in DM, C5b-9was mainly detected in endomysial capillaries. CD8 cells were more abundant in ASM than in DM (p < 0.05), and electively located in perimysium or in perifascular endomysium. HLA-DR expression correlated positively with the CD8+ cells infiltrates. Strictly similar observations were made in the confirmatory study. CONCLUSION: ASM is characterized by strong myofiber MHC-II/HLA-DR expression with a unique perifascicular pattern, not described so far. HLA-DR detection must be included for routine myopathological diagnosis of inflammatory/dysimmune myopathies. HLA-DR expression in ASM may indicate a specific immune mechanism, possibly involving IFNγ. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40478-014-0154-2) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4210467
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42104672014-10-29 Myofiber HLA-DR expression is a distinctive biomarker for antisynthetase-associated myopathy Aouizerate, Jessie De Antonio, Marie Bassez, Guillaume Gherardi, Romain K Berenbaum, Francis Guillevin, Loïc Berezne, Alice Valeyre, Dominique Maisonobe, Thierry Dubourg, Odile Cosnes, Anne Benveniste, Olivier Authier, François Jérôme Acta Neuropathol Commun Research OBJECTIVES: To assess the value of major histocompatibility complex (MHC) class II antigen (HLA-DR) expression to distinguish anti-synthetase myopathy (ASM) from dermatomyositis (DM). METHODS: Muscle biopsies from patients with ASM (n = 33), DM without anti-synthetase antibodies (ASAb) (n = 17), and normal muscle biopsy (n = 10) were first reviewed. ASAb included anti-Jo1 (26/33), anti-PL12 (4/33), anti-PL7 (2/33), and anti-EJ (1/33). Immunohistochemistry was performed for MHC-I/HLA-ABC, MHC-II/HLA-DR, membrane attack complex (C5b-9), neural cell adhesion molecule (NCAM)/CD56 expression, and inflammatory cell subsets. Twenty-four ASM and 12 DM patients from another center were added for HLA-DR evaluation. RESULTS: Ubiquitous myofiber HLA-ABC expression was equally observed in ASM and DM (93.9% vs 100%, NS). In contrast, myofiber HLA-DR expression was found in 27/33 (81.8%) ASM (anti-Jo1: 23/26, 88.5%; others: 5/7, 71.4%) vs 4/17 (23.5%) DM patients (p < 0.001). HLA-DR was perifascicular in ASM, a pattern not observed in DM. In addition, C5b-9 deposition was observed on sarcolemma of non-necrotic perifascicular fibers in ASM, while, in DM, C5b-9was mainly detected in endomysial capillaries. CD8 cells were more abundant in ASM than in DM (p < 0.05), and electively located in perimysium or in perifascular endomysium. HLA-DR expression correlated positively with the CD8+ cells infiltrates. Strictly similar observations were made in the confirmatory study. CONCLUSION: ASM is characterized by strong myofiber MHC-II/HLA-DR expression with a unique perifascicular pattern, not described so far. HLA-DR detection must be included for routine myopathological diagnosis of inflammatory/dysimmune myopathies. HLA-DR expression in ASM may indicate a specific immune mechanism, possibly involving IFNγ. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40478-014-0154-2) contains supplementary material, which is available to authorized users. BioMed Central 2014-10-23 /pmc/articles/PMC4210467/ /pubmed/25339355 http://dx.doi.org/10.1186/s40478-014-0154-2 Text en © Aouizerate et al.; licensee BioMed Central Ltd. 2014 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Aouizerate, Jessie
De Antonio, Marie
Bassez, Guillaume
Gherardi, Romain K
Berenbaum, Francis
Guillevin, Loïc
Berezne, Alice
Valeyre, Dominique
Maisonobe, Thierry
Dubourg, Odile
Cosnes, Anne
Benveniste, Olivier
Authier, François Jérôme
Myofiber HLA-DR expression is a distinctive biomarker for antisynthetase-associated myopathy
title Myofiber HLA-DR expression is a distinctive biomarker for antisynthetase-associated myopathy
title_full Myofiber HLA-DR expression is a distinctive biomarker for antisynthetase-associated myopathy
title_fullStr Myofiber HLA-DR expression is a distinctive biomarker for antisynthetase-associated myopathy
title_full_unstemmed Myofiber HLA-DR expression is a distinctive biomarker for antisynthetase-associated myopathy
title_short Myofiber HLA-DR expression is a distinctive biomarker for antisynthetase-associated myopathy
title_sort myofiber hla-dr expression is a distinctive biomarker for antisynthetase-associated myopathy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4210467/
https://www.ncbi.nlm.nih.gov/pubmed/25339355
http://dx.doi.org/10.1186/s40478-014-0154-2
work_keys_str_mv AT aouizeratejessie myofiberhladrexpressionisadistinctivebiomarkerforantisynthetaseassociatedmyopathy
AT deantoniomarie myofiberhladrexpressionisadistinctivebiomarkerforantisynthetaseassociatedmyopathy
AT bassezguillaume myofiberhladrexpressionisadistinctivebiomarkerforantisynthetaseassociatedmyopathy
AT gherardiromaink myofiberhladrexpressionisadistinctivebiomarkerforantisynthetaseassociatedmyopathy
AT berenbaumfrancis myofiberhladrexpressionisadistinctivebiomarkerforantisynthetaseassociatedmyopathy
AT guillevinloic myofiberhladrexpressionisadistinctivebiomarkerforantisynthetaseassociatedmyopathy
AT bereznealice myofiberhladrexpressionisadistinctivebiomarkerforantisynthetaseassociatedmyopathy
AT valeyredominique myofiberhladrexpressionisadistinctivebiomarkerforantisynthetaseassociatedmyopathy
AT maisonobethierry myofiberhladrexpressionisadistinctivebiomarkerforantisynthetaseassociatedmyopathy
AT dubourgodile myofiberhladrexpressionisadistinctivebiomarkerforantisynthetaseassociatedmyopathy
AT cosnesanne myofiberhladrexpressionisadistinctivebiomarkerforantisynthetaseassociatedmyopathy
AT benvenisteolivier myofiberhladrexpressionisadistinctivebiomarkerforantisynthetaseassociatedmyopathy
AT authierfrancoisjerome myofiberhladrexpressionisadistinctivebiomarkerforantisynthetaseassociatedmyopathy